Hurvitz Chaim 4
4 · NRX Pharmaceuticals, Inc. · Filed Nov 21, 2022
Insider Transaction Report
Form 4
Hurvitz Chaim
Director
Transactions
- Purchase
Common Stock
2022-11-16$0.99/sh+287,812$284,934→ 287,812 total - Purchase
Common Stock
2022-11-18$1.10/sh+40,408$44,449→ 500,000 total - Award
Employee Stock Option
2022-10-21+162,660→ 381,083 totalExercise: $0.75Exp: 2032-10-21→ Common Stock (162,660 underlying) - Purchase
Common Stock
2022-11-17$1.08/sh+171,780$185,522→ 459,592 total
Holdings
- 1,436,350(indirect: By IRA)
Common Stock
- 208,443(indirect: By CH Health-Private Venture Capital Ltd.)
Common Stock
Footnotes (4)
- [F1]The price reported above reflects the weighted average purchase price per share of common stock (the "Common Stock"), of NRx Pharmaceuticals, Inc. (the "Issuer"). The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected.
- [F2]The price reported above reflects the weighted average purchase price per share of the Common Stock. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected.
- [F3]The price reported above reflects the weighted average purchase price per share of the Common Stock. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common
- [F4]Options issued under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on May 25, 2023, generally subject to the Reporting Person's continued service for the Issuer.